| ¿µ¹® | meninges | ÇÑ±Û | ¼ö¸·, ³úô¼ö¸· |
|---|---|---|---|
| ¼³¸í | ³ú¸·Àº Å©°Ô 3Á¾·ùÀÇ ¸·À¸·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç, Á¦ÀÏ ¹Ù±ù¸·Àº »ÀÀ» ½Î°í ÀÖ´Â ¸·°úµµ ¿¬°áµÇ´Â °æÁú¸·(dura mater)À̰í, ±× ´ÙÀ½ °Å¹Ì¸·(arachnoid membrane), ±×¸®°í À¯¸·(pia mater)À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ÀÌÁß °Å¹Ì¸·°ú À¯¸·À» ÇÕÃļ ¿¬¼ö¸·(leptomeninges)À̶ó°í ºÎ¸£°í, ¸ÇÀ§ °æÁú¸·À» °æÁú¸·(pachymeninx)À̶ó ºÎ¸¥´Ù. °æÁú¸·ÀÇ ¹Ø°ø°£À» °ÑÁú¸·¹Ø°ø°£À̶ó ºÎ¸£´Âµ¥, ¿©±â¿¡´Â ¸¹Àº Ç÷°üÀÌ Áö³ª°£´Ù. ¶ÇÇÑ °Å¹Ì¸·ÀÇ ¹Ø°ø°£À» °Å¹Ì¸·¹Ø°ø°£À̶ó ºÎ¸£´Âµ¥ ¿©±â¿¡ ³úô¼ö¾×ÀÌ Â÷ÀÖ´Ù. À¯¸·(pia mater)ÀÇ ¹Ø¿¡´Â ¹Ù·Î ³úÁ¶Á÷ÀÌ Á¸ÀçÇϸç, À̸¦ ÅëÇØ ³úÁ¶Á÷À¸·Î °¡´Â Çǰ¡ µé¾î°¡°Ô µÈ´Ù(³úÇ÷°ü À庮=BBB: blood brain barrier: ³úÁ¶Á÷°ú ÇÇ»çÀÌ¿¡´Â ¹Ù·Î ±³ÅëÀÌ µÇ´Â °ÍÀÌ ¾Æ´Ï°í ÀÌ·± À庮À» ÅëÇØ¼¸¸ ¿µ¾çºÐÀÌ ³úÁ¶Á÷À¸·Î ±³È¯µÉ ¼ö ÀÖ´Ù). |
||
| ¿µ¹® | neoplasm | ÇÑ±Û | ½Å»ý¹° |
|---|---|---|---|
| ¼³¸í | »õ·Î »ý±ä ¹°ÁúÀ̶ó´Â ¶æÀÌ´Ù. À̰ÍÀº ´Ù¸¥ ¸»·Î ¡°Á¾¾ç(tumor)¡±À̶ó°íµµ ÇÏ´Â µ¥, ½ÇÁ¦·Î À̵éÀÇ ¸íÈ®ÇÑ ¶æÀº ¼·Î ´Ù¸£´Ù. Á¾¾çÀ̶ó´Â ¸»Àº ¡°±× Å©±â°¡ 1cm°¡ ³Ñ´Â ÀÏÁ¾ÀÇ È¤¡±À» ¸»ÇÏ´Â °ÍÀ¸·Î ÇǺΰú¿¡¼´Â À̺¸´Ù ÀÛÀº ȤÀ» ±¸ÁøÀ̶ó°í ÇÏ¿© ±¸º°ÇÏ¿© ºÎ¸¥´Ù. ÇÏÁö¸¸, À̰ÍÀº ¶ÇÇÑ ÇǺλӸ¸ ¾Æ´Ï¶ó ½Åü³» ¾îµð¿¡¼µç »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ¸ðµÎ ÅëĪÇÏ¿© Á¾¾çÀ̶ó°í ºÎ¸¥´Ù. ÀÌ¿¡ ºñÇØ ¡°½Å»ý¹°¡±Àº ½Åü³» ¾ø´ø °ÍÀÌ »õ·Î »ý°Ü³µ´Ù´Â ¶æÀ¸·Î ºÙÀÎ ¸»ÀÌ´Ù. ±×·¯³ª, ÀÌ µÑÀÇ °ü°è¸¦ ¸íÈ®È÷ ±ÔÁ¤ÁþÁö ¾Ê°í ÀÖÀ¸¸ç ´ë°³ °°Àº ¶æÀ¸·Î È¥¿ëµÈ´Ù. ½Å»ý¹°¿¡´Â ¡°¾ç¼º(benign)¡±°ú ¡°¾Ç¼º(malignant)¡±ÀÌ ÀÖ´Ù. ÀÌ µÑÀÇ ±¸º°Àº ¿©·¯ °¡Áö ±âÁØ¿¡ µû¸£Áö¸¸, ¶§·Î´Â ±¸º°ÀÌ ¾î·Á¿ï ¶§µµ ÀÖ´Ù. ´ë°³ ¾ç¼ºÀº »ý¸í´ÜÃàÀ» Àß ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î Ä¡·áÈÄ¿¡ Àç¹ßµµ Àß ÇÏÁö ¾Ê´Â´Ù. ÀÌ¿¡ ºñÇØ ¾Ç¼ºÀº Àç¹ß»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ±â°üÀ¸·Î ¿Å°Ü°¡¼ °°Àº º´º¯ÀÌ ¹ß»ýÇÏ´Â ¡°ÀüÀÌ(metastasis)¡±Çö»óµµ ÀϾÙ. µû¶ó¼ »ý¸íÀ» ´ÜÃà½ÃŰ´Â °æ¿ì°¡ ¸¹À¸¸ç, ´ë°³ Ä¡·á°¡ ¾î·Æ´Ù. |
||
| MGUS | Monoclonal Gammopathy of Uncertain Significance |
|---|---|
| SU | salicyluric acid; secretory unit; sensation unit; solar urticaria; sorbent unit; spectrophotometric ... |
| UE | uncertain etiology; under elbow; uninvolved epidermis; upper esophagus; upper extremity |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CBN | cannabinol; central benign neoplasm; Commission on Biological Nomenclature |
| MGUS | Monoclonal gammopathy of uncertain significance |
|---|---|
| SMN | Second Malignant Neoplasm |
| CBT | Cognitive Behaviour Therapy |
| DRO | Differential Reinforcement of Other Behaviour |
| FUO | Fever of Unknown Origin |
| meninges | <anatomy> The surrounding membranes the brain and spinal cord. There are three layers: the dura mater (outer), arachnoid membrane (middle) and the pia mater (inner layer). (27 Sep 1997) |
|---|---|
| uncertain | 1. Not certain; not having certain knowledge; not assured in mind; distrustful. "Man, without the protection of a superior Being, . . . Is uncertain of everything that he hopes for." (Tillotson) 2. Irresolute; inconsonant; variable; untrustworthy; as, an uncertain person; an uncertain breeze. "O woman! in our hours of ease, Uncertain, coy, and hard to please!" (Sir W. Scott) 3. Questionable; equivocal; indefinite; problematical. "The fashion of uncertain evils." "From certain dangers to uncertain praise." (Dryden) 4. Not sure; liable to fall or err; fallible. "Soon bent his bow, uncertain in his aim." (Dryden) "Whistling slings dismissed the uncertain stone." (Gay) Synonym: See Precarious. Origin: Pref. Un- + certain. Cf. Incertain. Source: Websters Dictionary (01 Mar 1998) |
| neoplasms, unknown primary | Metastases in which the tissue of origin is unknown. (12 Dec 1998) |
| fever of unknown origin | Fever in which the aetiology cannot be ascertained. (12 Dec 1998) |
| behaviour and behaviour mechanisms | The observable response made to a situation and the unconscious processes underlying it. (12 Dec 1998) |
| antibodies, neoplasm | Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens. (12 Dec 1998) |
| antigens, neoplasm | Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. (12 Dec 1998) |
| brain neoplasm | Neoplasms of the part of the central nervous system contained within the cranium. (12 Dec 1998) |
| genes, structural, neoplasm | DNA sequences that code for RNA and for the proteins required for the enzymatic and structural function of neoplastic cells. (12 Dec 1998) |
| mucinous cystic neoplasm of pancreas | <radiology> = macrocystic adenoma of pancreas, cystadenoma / cystadenocarcinoma, M:F = 1:9, 40-60 years of age, malignant or pre-malignant, large mass (mean 12 cm), multilocular cysts, thick septations, tail / body in 85% (unlike adenocarcinoma and microcystic adenoma), hypo-/avascular, Differential diagnosis: panc pseudocyst, ** Cf: microcystic adenoma (12 Dec 1998) |
| histoid neoplasm | Old term for a neoplasm characterised by a cytohistologic pattern that closely resembles the tissue from which the neoplastic cells are derived. (05 Mar 2000) |
| neoplasm | <oncology, pathology> New and abnormal growth of tissue, which may be benign or cancerous. (16 Dec 1997) |
| neoplasm circulating cells | Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumours. (12 Dec 1998) |
| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
| neoplasm invasiveness | Ability of neoplasms to infiltrate and actively destroy surrounding tissue. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|